Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175954
Title: | Polymer-based or polymer-free stents in patients at high bleeding risk |
Author: | Windecker, Stephan Latib, Azeem Kedhi, Elvin Kirtane, Ajay J. Kandzari, David E. Mehran, Roxana Price, Matthew J. Abizaid, Alexandre Simon, Daniel I. Worthley, Stephen G. Zaman, Azfar Hudec, Martin Poliacikova, Petra Abdul Ghapar, Kahar Bin Selvaraj, Kamaraj Petrov, Ivo Mylotte, Darren Pinar, Eduardo Moreno, Raúl Fabbiocchi, Franco Pasupati, Sanjeevan Kim, Hyo-Soo Aminian, Adel Tie, Charles Wlodarczak, Adrian Hur, Seung-Ho Marx, Steven O. Jankovic, Ivana Brar, Sandeep Bousquette, Lisa Liu, Minglei Stone, Gregg W. ONYX ONE Investigators (Cequier, A.) |
Keywords: | Artèries coronàries Efectes secundaris Immunosupressió Ús terapèutic Polímers Coronary arteries Side effects Immunosuppression Therapeutic use Polymers |
Issue Date: | 26-Mar-2020 |
Publisher: | Massachusetts Medical Society |
Abstract: | Background: polymer-free drug-coated stents provide superior clinical outcomes to bare-metal stents in patients at high bleeding risk who undergo percutaneous coronary intervention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on the use of polymer-based drug-eluting stents, as compared with polymer-free drug-coated stents, in such patients are limited. Methods: in an international, randomized, single-blind trial, we compared polymer-based zotarolimus-eluting stents with polymer-free umirolimus-coated stents in patients at high bleeding risk. After PCI, patients were treated with 1 month of dual antiplatelet therapy, followed by single antiplatelet therapy. The primary outcome was a safety composite of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year. The principal secondary outcome was target-lesion failure, an effectiveness composite of death from cardiac causes, target-vessel myocardial infarction, or clinically indicated target-lesion revascularization. Both outcomes were powered for noninferiority. Results: a total of 1996 patients at high bleeding risk were randomly assigned in a 1:1 ratio to receive zotarolimus-eluting stents (1003 patients) or polymer-free drug-coated stents (993 patients). At 1 year, the primary outcome was observed in 169 of 988 patients (17.1%) in the zotarolimus-eluting stent group and in 164 of 969 (16.9%) in the polymer-free drug-coated stent group (risk difference, 0.2 percentage points; upper boundary of the one-sided 97.5% confidence interval [CI], 3.5; noninferiority margin, 4.1; P = 0.01 for noninferiority). The principal secondary outcome was observed in 174 patients (17.6%) in the zotarolimus-eluting stent group and in 169 (17.4%) in the polymer-free drug-coated stent group (risk difference, 0.2 percentage points; upper boundary of the one-sided 97.5% CI, 3.5; noninferiority margin, 4.4; P = 0.007 for noninferiority). Conclusions: among patients at high bleeding risk who received 1 month of dual antiplatelet therapy after PCI, use of polymer-based zotarolimus-eluting stents was noninferior to use of polymer-free drug-coated stents with regard to safety and effectiveness composite outcomes. (Funded by Medtronic; ONYX ONE ClinicalTrials.gov number, NCT03344653.). |
Note: | Reproducció del document publicat a: https://doi.org/10.1056/NEJMoa191002 |
It is part of: | New England Journal of Medicine, 2020, vol. 382, num. 13, p. 1208-1218 |
URI: | http://hdl.handle.net/2445/175954 |
Related resource: | https://doi.org/10.1056/NEJMoa191002 |
ISSN: | 0028-4793 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
706449.pdf | 661.6 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.